PDCD1 and glioblastoma: A decrease in CD11c+CD14+CD16+HLA-DRhi monocytes, accompanied by a significant increase in overall survival (OS), has been observed in recurrent glioblastoma after post-surgery Pembrolizumab, but only in patients that had also received neo-adjuvant anti-PD-1 immunotherapy before surgery (53).